Who'll Swallow Bayer?

When German conglomerate Bayer announced late last year that it is seeking a majority partner for its drug business, speculation swirled that a rival pharmaceutical giant would snap it up. Bayer seemed attractive not for its illustrious past (the company launched the modern pharmaceutical industry with its 1897 invention of aspirin) or high-volume present (it has annual pharma revenues of j4.8 billion), but for its future: the company has a sexual-potency drug, Levitra, ready to come on the market this year, which is touted as the next Viagra. The prize is almost certainly worth billions in sales.


Want the full story?

Subscribe Now


Get TIME the way you want it

  • One Week Digital Pass — $4.99
  • Monthly Pay-As-You-Go DIGITAL ACCESS$2.99
  • One Year ALL ACCESSJust $30!   Best Deal!
    Print Magazine + Digital Edition + Subscriber-only Content on TIME.com

Learn more about the benefits of being a TIME subscriber

If you are already a subscriber sign up — registration is free!